The 14-3-3/spastin pathway coordinates neurite regeneration and recovery of spinal cord injury by targeting microtubule dynamics

Reviewer #1 (Public Review):

The present work establishes 14-3-3 proteins as binding partners of Spastin and suggests that this binding is positively regulated by phosphorylation of Spastin. The authors show evidence that 14-3-3 - Spastin binding prevents Spastin ubiquitination and final proteasomal degradation, thus increasing the availability of Spastin. The authors measured microtubule severing activity in cell lines and axon regeneration and outgrowth as a prompt to Spastin activity. By using drugs and peptides that separately inhibit 14-3-3 binding or Spastin activity, they show that both proteins are necessary for axon regeneration in cell culture and in vivo models in rats.

The following is an account of the major strengths and weaknesses of the methods and results.

Major strengths
-The authors performed pulldown assays on spinal cord lysates using GST-spastin, then analyzed pulldowns via mass spectrometry and found 3 peptides common to various forms of 14-3-3 proteins. In co-expression experiments in cell lines, recombinant Spastin co-precipitated with all 6 forms of 14-3-3 tested.
-By protein truncation experiments they found that the Microtubule Binding Domain of Spastin contained the binding capability to 14-3-3. This domain contained a putative phosphorylation site, and substitutions that cannot be phosphorylated cannot bind to Spastin.
-Spastin overexpression increased neurite growth and branching, and so did the phospho null spastin. On the other hand, the phospho mimetic prevents all kinds of neurite development.
-Overexpression of GFP-Spastin shows a turn-over of about 12 hours when protein synthesis is inhibited by cycloheximide. When 14-3-3 is co-overexpressed, GFP-Spastin does not show a decrease by 12 hours. When S233A is expressed, a turn-over of 9 hours is observed, indicating that the ability to be phosphorylated increases the stability of the protein.
-In support of that notion, the phospho-mimetic S233D makes it more stable, lasting as much as the over-expression of 14-3-3.
-Authors show that Spastin can be ubiquitinated, and that in the presence of ubiquitin, Spastin-MT severing activity is inhibited.
-By combining FCA with Spastazoline, the authors claim that FCA increased regeneration is due to increased Spastin Activity in various models of neurite outgrowth and regeneration in cell culture and in vivo, the authors show impressive results on the positive effect of FCA in regeneration, and that this is abolished when Spastin is inhibited.

Major weaknesses
-However convincing the pull-downs of the expressed proteins, the evidence would be stronger if a co-immunoprecipitation of the endogenous proteins were included.
-To better establish the impact of Spastin phosphorylation in the interaction, there is no indication that the phosphomimetic (S233D) can better bind Spastin, and this result is contradicting to the conclusion of the authors that Spastin-14-3-3 interaction is necessary for (or increases) Spastin function
-To fully support the authors' suggestion that 14-3-3 and Spastin work in the same pathway to promote regeneration, I believe that some key observations are missing.
1-There is no evidence showing that 14-3-3 overexpression increases the total levels of Spastin, not only its turnover.
2- There is no indication that increasing the ubiquitination of Spastin decreases its levels. To suggest that proteasomal activity is affecting the levels of a protein, one would expect that proteasomal inhibition (with bortezomib or epoxomycin), would increase its levels.
3- Authors show that S233D increases MT severing activity, and explain that it is related to increased binding to 14-3-3. An alternative explanation is that phosphorylation at S233 by itself could increase MT severing activity. The authors could test if purified Spastin S233D alone could have more potent enzymatic activity.
-Finally, I consider that there are simpler explanations for the combined effect of FC-A and spastazoline. FC-A mechanism of action can be very broad, since it will increase the binding of all 14-3-3 proteins with presumably all their substrates, hence the pathways affected can rise to the hundreds. The fact that spastazoline abolishes FC-A effect, may not be because of their direct interaction, but because Spastin is a necessary component of the execution of the regeneration machinery further downstream, in line with the fact that spastizoline alone prevented outgrowth and regeneration, and in agreement with previous work showing that normal Spastin activity is necessary for regeneration.

In summary, the evidence of the interaction of 14-3-3 and Spastin is solid, but it is weak with respect to showing evidence for the binding of endogenous proteins in neurons. Another strength of the manuscript is the important recovery of function after spinal cord injury after stimulation of 14-3-3 interactions. Although it is experimentally difficult to demonstrate that the effect of FC-A is due to the prevention of Spastin ubiquitination, the effect itself is very robust and remarkable in vivo.

Reviewer #2 (Public Review):

Summary:
The idea of harnessing small molecules that may affect protein-protein interactions to promote axon regeneration is interesting and worthy of study. In this manuscript, Liu et al. explore a 14-3-3-Spastin complex and its role in axon regeneration.

Strengths:
Some of the effects of FC-A on locomotor recovery after spinal cord contusion look interesting.

Weaknesses:
The manuscript falls short of establishing that a 14-3-3-Spastin complex is important for any FC-A-dependent effects and there are several issues with data quality that make it difficult to interpret the results. Importantly, the effects of the Spastin inhibitor have a major impact on neurite outgrowth suggesting that cells simply cannot grow in the presence of the inhibitor and raising serious questions about any selectivity for FC-A - dependent growth. Aspects of the histology following spinal cord injury were not convincing.

Reviewer #3 (Public Review):

Summary:
The current manuscript claims that 14-3-3 interacts with Spastin and that the 14-3-3/spastin interaction is important to regulate axon regeneration after spinal cord injury.

Strengths:
In its present form, this reviewer identified no clear strengths for this manuscript.

Weaknesses:
In general, most of the figures lack sufficient quality to allow analyses and support the author's claims (detailed below). The legends also fail to provide enough information on the figures which makes it hard to interpret some of them. Most of the quantifications were done based on pseudo-replication. The number of independent experiments (that should be defined as n) is not shown. The overall quality of the written text is also low and typos are too many to list. The original nature of the spinal cord injury-related experiments is unclear as the role of 14-3-3 (and Spastin) in axon regeneration has been extensively explored in the past.